Therefore, although considered as part of type 2 immunity, studies are consistent with IL-9 inducing anti-tumour immunity through cross-activating type 1 immune INFγ producing cells such as CD8+ T cells and Th1 cells [155, 158]. The gene discussed is IL9; the disease is neoplasm.